Skip to content
Research Article Open access CC BY 3.0

CYP2C19 Genetic Polymorphism of Cytochrome p450 Enzyme in Iranian Fars Ethnic Group

Robabeh Ghiyas Tabari, Ogholdondy Agh Ataby, Abdoljalal Marjani

Annual Research & Review in Biology · pp. 1471–1479 · Published 28 Jan 2014

10.9734/ARRB/2014/7755

Abstract

Aim: There are differences in the frequency of CYP2C19 mutant alleles among different ethnic group. The aim of present study was to estimate the distribution of CYP2C19 allele and genotypic variants in Iranian Fars ethnic group and compare it with other populations. Study Design: Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) technique was used to determine Genotyping of CYP2C19 alleles. Place and Duration of Study: Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, between September 2012 and August 2013. Methodology: To determine the genotype and allelic frequency of CYP2C19, 140 unrelated healthy Fars origin people who were referred to Health Center, were included this study. Results: The allele frequency of CYP2C19*1, CYP2C19*2 and CYP2C19*3 were 77.8%, 19.2% and 2.8%, respectively. 75% of subjects were with CYP2C19*1/*1 genotype. 22.1%, 1.4%, 1.4%, 0% and 0% subjects were with CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3 and CYP2C19*3/*3 genotypes, respectively. Poor metabolizer, intermediate metabolizer and extensive metabolizers genotype frequencies were seen in 75%, 23.5% and 1.4% of subjects, respectively. Conclusion: Ethnic differences in CYP2C19 genetic polymorphism of cytochrome p450 enzyme may cause variation in drug response, activity or detoxification. This study suggests the further study of this polymorphic enzyme in Fars population to determine the clinical significance and optimal dosage of some drugs in this ethnic group.

CYP2C19 polymorphism fars polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP).

References (24)

  1. 1 A simple salting out procedure for extracting DNA from human nucleated cells [DOI]
  2. 2 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. [DOI]
  3. 3 Cytochrome P4502C9: an enzyme of major importance in human drug metabolism [DOI]
  4. 4 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. [DOI]
  5. 5 Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation [DOI]
  6. 6 Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population [DOI]
  7. 7 Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population [DOI]
  8. 8 Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [DOI]
  9. 9 Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients [DOI]
  10. 10 Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population [DOI]
  11. 11 Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations [DOI]
  12. 12 CYP2C19 genotype and phenotype determined by omeprazole in a Korean population [DOI]
  13. 13 GENETIC POLYMORPHISMS OF CYTOCHROME P450 ENZYMES 2C9 AND 2C19 IN A HEALTHY IRANIAN POPULATION [DOI]
  14. 14 Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran [DOI]
  15. 15 Genetic polymorphism of S-mephenytoin hydroxylation [DOI]
  16. 16 Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese [DOI]
  17. 17 A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype [DOI]
  18. 18 Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations [DOI]
  19. 19 High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu [DOI]
  20. 20 CYP2C19 genetic mutations in North Indians [DOI]
  21. 21 Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals [DOI]
  22. 22 Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations [DOI]
  23. 23 GENETIC POLYMORPHISM OF CYTOCHROMES P450 2C9 AND 2C19 IN SLOVENIAN POPULATION
  24. 24 Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics [DOI]

Cited by 1

Proton pump inhibitors in Iranian population: from clinical regimens to pharmacogenomics

K. Bagherzadeh, Sepideh Safari, M. Amanlou · 2020

Related research

Article metrics

Real usage data collected on this platform.

47

Page views

0

PDF downloads

8

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.